Ovid Therapeutics Inc. (OVID): Price and Financial Metrics
OVID Price/Volume Stats
| Current price | $3.64 | 52-week high | $4.14 |
| Prev. close | $3.61 | 52-week low | $1.40 |
| Day low | $3.40 | Volume | 108,600 |
| Day high | $3.68 | Avg. volume | 172,755 |
| 50-day MA | $3.60 | Dividend yield | N/A |
| 200-day MA | $2.98 | Market Cap | 256.99M |
OVID Stock Price Chart Interactive Chart >
OVID POWR Grades
- OVID scores best on the Sentiment dimension, with a Sentiment rank ahead of 89.53% of US stocks.
- The strongest trend for OVID is in Growth, which has been heading down over the past 179 days.
- OVID's current lowest rank is in the Momentum metric (where it is better than 16.64% of US stocks).
OVID Stock Summary
- The capital turnover (annual revenue relative to shareholder's equity) for OVID is 0 -- better than just 8.63% of US stocks.
- OVID's price/sales ratio is 1,347.75; that's higher than the P/S ratio of 99.57% of US stocks.
- As for revenue growth, note that OVID's revenue has grown -86.26% over the past 12 months; that beats the revenue growth of merely 1.65% of US companies in our set.
- If you're looking for stocks that are quantitatively similar to OVID THERAPEUTICS INC, a group of peers worth examining would be VHC, ENTX, GANX, LXRX, and NAVB.
- OVID's SEC filings can be seen here. And to visit OVID THERAPEUTICS INC's official web site, go to www.ovidrx.com.
OVID Valuation Summary
- In comparison to the median Healthcare stock, OVID's EV/EBIT ratio is 134.68% lower, now standing at -4.3.
- Over the past 78 months, OVID's price/earnings ratio has gone up 8.
Below are key valuation metrics over time for OVID.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| OVID | 2023-09-18 | 1344.7 | 2.4 | -5.4 | -4.3 |
| OVID | 2023-09-15 | 1408.5 | 2.5 | -5.7 | -4.5 |
| OVID | 2023-09-14 | 1362.3 | 2.4 | -5.5 | -4.3 |
| OVID | 2023-09-13 | 1295.0 | 2.3 | -5.2 | -4.1 |
| OVID | 2023-09-12 | 1295.0 | 2.3 | -5.2 | -4.1 |
| OVID | 2023-09-11 | 1241.7 | 2.2 | -5.0 | -3.9 |
OVID's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- OVID has a Quality Grade of C, ranking ahead of 59.21% of graded US stocks.
- OVID's asset turnover comes in at 1.419 -- ranking 13th of 682 Pharmaceutical Products stocks.
- QURE, ACER, and SCYX are the stocks whose asset turnover ratios are most correlated with OVID.
The table below shows OVID's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 1.419 | 1 | -10.143 |
| 2021-03-31 | 1.963 | 1 | -8.584 |
| 2020-12-31 | 0.184 | 1 | 18.535 |
| 2020-09-30 | 0.099 | 1 | -10.445 |
| 2020-06-30 | 0.000 | NA | -8.770 |
| 2020-03-31 | 0.000 | NA | -6.119 |
OVID Price Target
For more insight on analysts targets of OVID, see our OVID price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $4.75 | Average Broker Recommendation | 1.5 (Moderate Buy) |
Ovid Therapeutics Inc. (OVID) Company Bio
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company was founded in 2014 and is based in New York City, New York.
Latest OVID News From Around the Web
Below are the latest news stories about OVID THERAPEUTICS INC that investors may wish to consider to help them evaluate OVID as an investment opportunity.
Ovid Therapeutics to Present at the 2023 Cantor Fitzgerald Global Healthcare ConferenceNEW YORK, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today announced that management will participate in a panel presentation at the 2023 Cantor Fitzgerald Global Healthcare Conference on Tuesday, September 26, 2023, at 9:55 a.m. ET in New York, New York. A live webcast of the Cantor Fitzgerald presentation can be accessed |
Ovid Therapeutics to Participate in Upcoming September Investor ConferencesNEW YORK, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today announced that management will participate in two upcoming investor conferences. Citi’s 18th Annual BioPharma Conference – Ovid will participate on Thursday, September 7, 2023 in Boston, Massachusetts. The H.C. Wainwright 25th Annual Global Investment Conference – Ov |
3 Very Promising Penny Stocks That Are Flying Under the RadarAlthough the very concept of penny stocks to buy screams risk, these ideas just might be intriguing enough for speculators. |
Ovid Therapeutics (OVID) Reports Q2 Loss, Lags Revenue EstimatesOvid Therapeutics (OVID) delivered earnings and revenue surprises of 14.29% and 17.58%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock? |
Ovid Therapeutics Reports Second Quarter 2023 Financial Results and Corporate UpdatesCompleted single ascending dose (SAD) portion of Phase 1 trial evaluating OV329, a potential next-generation GABA-aminotransferase inhibitor Executed equity investment and initiated collaboration with Graviton Bioscience to develop highly selective ROCK2 inhibitors for rare neurological conditionsExpanded scientific leadership team with appointments of Chief Scientific Officer and Chief Medical Officer Regulatory filings for soticlestat in Lennox-Gastaut syndrome and Dravet syndrome continue to |
OVID Price Returns
| 1-mo | -7.96% |
| 3-mo | 6.74% |
| 6-mo | 27.72% |
| 1-year | 96.76% |
| 3-year | 30.00% |
| 5-year | 28.62% |
| YTD | 95.70% |
| 2022 | -42.06% |
| 2021 | 38.96% |
| 2020 | 11.33% |
| 2019 | 71.49% |
| 2018 | -75.48% |
Loading social stream, please wait...